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I NTROD U CTlON 
Morbidity and mortality attributed to severe bacterial 
infections are still major complications in modern 
medicine. Early recognition and prompt treatment can 
reduce morbidity and mortality. Better comprehension 
of the pathogenesis of sepsis and the response of the 
host organism have led to new definitions of sepsis 
(Table 1) [l]. Kecent studies suggest that the systemic 
inflammatory response syndrome (SIRS), sepsis, severe 
sepsis and septic shock represent different stages of the 
inflammatory response to infection [2]. 
Clinical diagnosis based on heart rate, respiratory 
rate, hypotension, fever, prostration and mental con- 
fusion is often difficult and non-specific. Parameters 
such as white blood cell (WBC) count, shift to the left 
in differential count, elevated C reactive protein (CRP) 
or increased erythrocyte sedimentation rate (ESR) can 
be useful, but are ofien not specific or sensitive enough. 
Table 2 shows the sensitivity, specificity and positive 
and negative predictive values for these tests. Cultures 
are often negative due to prior antimicrobial treatment 
or because adequate material is not readily available. 
The low sensitivity of blood cultures in the diagnosis 
of severe infections (range 17-69%) has led to the 
definition of culture-negative sepsis. This broad range 
in sensitivity is due to differences in defining and 
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classifying the severity of infection. In a large pro- 
spective study, the outcome in patients with culture- 
negative septic shock was similar to that in patients 
with microbiologically proven septic shock [2]. Van 
Griethuysen et a1 reported a sensitivity and specificity 
of 53% and 83%, respectively, for temperature >38.S°C 
[3]. In our study population of 337 episodes, we 
calculated a sensitivity and specificity of 40% and 65%, 
respectively, using the threshold suggested by van 
Griethuysen et a1 [3] (unpublished data). The positive 
and negative predictive values for fever are given in 
Table 2. 
The position of cytokines in the diagnosis and 
prognosis of severe infections is not yet defined and is 
controversial. Interleulun-6 (IL-6) is found earlier than 
C R P  in severe infections, but it is not sensitive enough 
to serve alone in the diagnosis of severe infections [4,5]. 
Tumor necrosis factor (TNF) is known to rise early 
during acute bacterial infection, but declines rapidly 
after a peak of only a few hours, resulting in a low 
sensitivity [4,6]. There are few data available on other 
diagnostic parameters in the diagnosis of sepsis, such as 
phospholipase Az, interferon-y, neopterin or soluble 
CD14; too few episodes have been studied to allow 
definite conclusions, and often complicated laboratory 
procedures are required [6-91. 
PROCALCITONIN 
The CALC-I gene encoding the polypeptide hor- 
mone calcitonin was one of the first examples of 
tissue-specific expression of m R N A  transcripts [lo]. 
The human CALC-I gene contains six exons [ l l ] .  
Its predominant product calcitonin, which regulates 
Ca*'metabolism, is produced by thyroid C-cells, 
whereas other related peptides are found in neuronal 
cells. Calcitonin is generated by proteolytic separation 
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Table 1 Definitions of the Consensus Conference of the American College of Chest Physician, 11 1 
Systemic inflammatory response syndrome (SIRS) 
Two o r  inore of the following: 
1 .  Teiiipcratwc > 3 8 T  o r  <30”(: 
2. Heart rate >OO bears/mm 
3 .  Rcyira tory  rate >20 breatlisiiiiin 
4. White blood cell count >12. l lX 10‘J/L. < I . l JX  l l l ” /L ,  or > O . I  immature forms (bmds) 
Sepsis 
SIRS plu\ ,i docunieiited infecrioi~ (po\itive a l t i i r r  b i -  orgmimi) 
Severe sepsis 
Sepm associated \\it11 organ dvsfuiiction, hypoprifuuon .horiiialities, or hypiitcnsion. (Hypopcrf-usimi abnoriii.ilitiey iiicludc, but x e  i i i x  
liiiiitetl to. lartir ac idom,  oliguria. or an ac-iitc alterarion of the mental st‘ituy) 
Septic shock 
Srpsi\-iriduccd hypotension d a p i t c  fluid resumtation plus Iiypopcritisioii ~biioriiialitiey 
Culture-negative sepsis 
SIKS plu5 eniplricd antibiotic treatment for clinically suspected infcctlon 111 xvliich n l l  cultures \ \we  n i ~ g t i v c  
Culture-negative severe sepsis 
SIRS a\wciatcd xvith organ dysfunction, hypoperiiisioti ~ ib i ior in~l i t ie~ .  oi- hypotensioti 
Culture-negative septic shock 
SIKS ‘issociatcd with hypotcnsion despite fluid resu~ciratiim plus hypopedus~ori abnoriiicilities. All culttile\ were neg‘itive. yet empirical 
m r i b ~ o t i c ~  treatiiieiit h i -  a clinically sucpected infectioii was prescribed 
Table 2 Sensitivitv and specificity and negative and poutive predictive valuc of tcnipcraturc. WBC count. ESK. CXP. blood 
culture$ atid procalcitonin (PCT) in patients with sepsis 
Scllrltlvlty Specificity I’ositive predictive Neparive predictive 
Iicfcwncr (%) (%) value (““I) \ - R i l l e  (x) 
17-65 
0 3 
5 3 
4 I 
73  _ _  
37 
7( I
I, 7 
47 
I1 
NA 
NA 
8.3 
6 5 
32 
6 7 
5 5 
6 9 
0 X 
7 9 
NA 
N A  
4 i 
50 
1s 
71) 
43 
51 
38 
f) I 
YA 
NA 
xs 
10 
X i  
X 0 
7X 
X I  
77 
7 X  
UI). iinpubh\hed d n t x  NA. not nvailable. 
from the larger prehornione, procalcitonin (PCT), 
which consists of 1 1 6 amino acids [ 121. These peptides 
have already been used as markers in medullary thyroid 
carcinoma and in a nuinbcr of other malignant 
pi-ocesses [ 13-16], I n  some of these cases, particularly 
lung cancer, PCT is found to be elevated without the 
pi-esence of  mature calcitonin. However, the biological 
role ofthis mechanism and the function of P C T  reniairi 
unknown. T h e  first hints about a mitogenic activiq of  
PCT on huiiian osteoblartic cells led to speculationc 
about its use in patients with osteoporosis 17-20]. 
111 healthy volunteers, I’CT serum coilcentrations 
arc below 0.15 ng/niL. although there may be a peak 
in the first day of life which is independent of a n  
infectious ctimulus 131,331. The threshold value of  
PCT in patients with SIKS a id  suspected sepsis seems 
to be 0.5 ng/niL [23.24]. 
P C T  is deter mined semi-au tonia ti cally m-ith an 
iinrnunolurniiionietric assq- using antibody-coated tubes 
in a luininonieter. T h e  test is specific for PCT, lvith a 
detection limit of  0 . 1  ng/mL a n d  good reproducibility 
T h e  nssay uses two iiionoclonal mtibodies. O n e  is a 
capture antibody directed against the 96-1 Oh sequence 
iii PCT, and the other i\ ‘1 tracer mtibody directed 
against the 70-76 residues 1211. At rooiii ternperaturr 
‘1 reduction in P C T  plasnia concentrations of  12.394 
per 21 h is reported. There seems to be no significant 
influence of  the blood sampling technique (arterial or 
venous line) or of repeated ~reeziiig-tlia\~-i-iri~ cycles on 
the P C T  concentrations I2.J. 
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As calcitonin and calcitonin-related peptides have 
been found in human neuroendocrine lung cells 
[26,27], efforts were first made to determine PCT in 
patients with inhalatory injuries following burns [28,29]. 
Here it is found at high concentrations without the 
presence of mature calcitonin. Higher concentrations 
of PCT correlated with mortality but not always with 
the burnt body-surface area. In some instances PCT 
remains elevated even after spirometry measurements 
return to normal values, indicating a long-term response 
of pulmonary neuroendocrine cells to burns [30]. In 
the same study, PCT and IL-6 concentrations were not 
associated with smoke inhalation or infection. 
To investigate the role of I’CT in severe infections, 
Dandona et a1 measured PCT concentrations in healthy 
volunteers after the injectiori of endotoxins derived 
from Eschericliia coli [21]. TNF-a levels peaked very 
early after 90-min and fell to baseline levels after 6 h. 
IL-6 increased more gradually, peaking after 3 h and 
reaching the baseline concentration after 8 h. PCT 
peaked after 6 h and remained at a plateau for more 
than 24 h. In patients with bacterial and aspiration 
pneumonia, PCT is found to be only moderately 
elevated, correlating with the radiographic changes 
[31,32]. Values of up to 2 ng/mL are found on the first 
days of an episode. 
There are only a few clirdcal studies investigating 
the position of PCT in the diagnosis and prognosis of 
infections. Assicot et a1 [33] were the first to report 
PCT serum levels in 79 pediatric patients; 19 of them 
had severe bacterial infection., with serum PCT con- 
centrations ranging from 6 to 53 ng/mL. Patients with 
local infection or viral infection had lower values. They 
reported a close relation with infectious complications. 
We prospectively studied 337 adult patients admitted 
to an internal medicine department with suspected 
infection [24]. Patients who were classified as having 
SIRS had significantly lower PCT levels than patients 
with SIRS and in addition infection or septicemia 
or septic shock (Table 3). Other authors have found 
Table 3 Maxlmum PCT values from days 0 and 1 in 337 
patients with suspected sepsis [24] 
Group 
Mean PCT Standard No. of 
(ng/mL) deviation cases 
1. SIRS only 0.6 2.2 215 
2. SIRS + infection, 6.6 22.5 53 
3. SIRS + septicemia 8.5 19.0 49 
4. SIRS + septic shock 34.7 68.4 20 
Entire population 4.7 21.6 337 
microbiologically proven 
PCT levels above 1 ng/niL only in patients with septic 
shock. The causative organism (whether a Grani- 
negative or Gram-positive bacterium, or another micro- 
organism such as a Plasmodium species or fungus) 
does not significantly influence the level of PCT in 
serum. Also, episodes with culture-negative sepsis 
are characterized by elevated PCT concentrations [34]. 
Imrnunocompromised patients (HIV infection or malig- 
nant diseases) also appear to show high serum PCT 
concentrations during sepsis, but leukopenia seems to 
be associated with lower PCT values after day 2 of the 
sepsis episode [23,24]. It has been reported that PCT 
may serve as a useful marker for the detection of 
systemic bacterial infection in patients with systemic 
autoimmune disease [35]. In the same study no cor- 
relation was seen between the degree of renal impair- 
ment and PCT concentrations. 
Data are also available on PCT concentrations in 
neonatal infections. There seems to be a normal peak 
PCT concentration in healthy newborns in the first 
few hours after birth, soon declining to baseline levels. 
The available data suggest that in neonates with severe 
infections PCT levels rise more rapidly than C R P  
levels and that the sensitivity is higher [22]. In pediatric 
patients PCT seems to distinguish better between 
bacterial and viral meningitis than CRP or an assay of 
cells and protein in cerebrospinal fluid [33,36]. 
There is limited information on PCT concen- 
trations after surgical procedures. Efforts have been 
made to use PCT in the diagnosis of acute rejection of 
heart transplants. Patients with acute cellular rejection 
of the transplanted heart showed no circulating PCT; 
however, patients with bacterial or fungal infection 
showed moderate to high levels of PCT [37]. 
Elevated PCT levels have also been reported in 
tropical diseases. In patients with melioidosis due to 
Burkholderia pseudomallei, initial high PCT values have 
been reported to have prognostic value for higher 
mortality [38]. In Asian as well as European populations 
with malaria, PCT is elevated, reaching values over 
100 ng/mL. This seems to correlate with severity. In 
the first few hours of infection, PCT values reach peak 
levels, declining rapidly under therapy [39,40]. 
Few data are available on the prognostic usefulness 
of PCT in patients with severe infections. In a study on 
30 intensive care unit patients with sepsis or septic 
shock, PCT seemed to be higher in non-surviving 
patients than in survivors. CRF’, TNF-a,  neopterin, 
and IL-6 were not significantly correlated with the 
outcome of the infection [41]. In our study of 337 
episodes, PCT levels were followed for 9 days. O n  
admission, the mean PCT value for survivors was 
4.4 ng/mL, whereas for non-survivors the mean values 
was 15.2 ng/mL p=0.002). 
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CONCLUSION 
Although many tests are available in the diagnosis of 
severe infection, there is a need for more sensitive and 
specific diagnostic tools. The monitoring of success or 
failure of anti-infective therapy, especially in critically 
ill patients, is still unsatisfactory. Many studies have 
independently shown that PCT is elevated early in 
episodes of severe infections. However, there are large 
interindividual differences which seem not to be related 
to the disease. Differences in the definition of sepsis and 
sevcrc infection may lead to conflicting results. 
There are few statistically significant data on the 
threshold of PCT in diagnosis of severe infections, as 
most studies do not contain enough cases to lead to 
statistically established statements. The normal values 
for I'CT in a healthy population are well established, 
but there are not enough studies on I'CT values in 
patients with non-infectious diseases. The prognostic 
value of PCT needs to be established in larger study 
populations. The number of cases studied so far is 
limited, and it seenis that if PCT is initially elevated and 
doe5 not decline in the course of infection the mortality 
is higher. This is also the case in patients who do not 
respond to antimicrobial treatment. Multicenter studies 
are required to resolve these issues. The mechanism of 
elevated seruni I'CT levels in patients with severe 
infections is not well understood. However, it may be 
useful to elucidate the role of PCT in the pathologic 
mechanisms in severe infections, as this may lead to 
better utilization of this promising laboratory para- 
meter. 
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